The pandemic of
COVID-19 has caused >5 million deaths in the world. One of the leading causes of the severe form of
COVID-19 is the production of massive amounts of proinflammatory
cytokines. Epigenetic mechanisms, such as
histone/DNA methylation,
miRNA, and
long noncoding RNA, are known to play important roles in the regulation of
inflammation. In this study, we investigated if hospitalized
COVID-19 patients exhibit alterations in epigenetic pathways in their PBMCs. We also compared gene expression profiles between healthy controls and
COVID-19 patients. Despite individual variations, the expressions of many
inflammation-related genes, such as
arginase 1 and
IL-1 receptor 2, were significantly upregulated in
COVID-19 patients. We also found the expressions of coagulation-related genes
Von Willebrand factor and
protein S were altered in
COVID-19 patients. The expression patterns of some genes, such as
IL-1 receptor 2, correlated with their
histone methylation marks. Pathway analysis indicated that most of those dysregulated genes were in the TGF-β, IL-1b,
IL-6, and
IL-17 pathways. A targeting pathway revealed that the majority of those altered genes were targets of
dexamethasone, which is an approved drug for
COVID-19 treatment. We also found that the expression of bone marrow
kinase on chromosome X, a member of TEC family
kinases, was increased in the PBMCs of
COVID-19 patients. Interestingly, some inhibitors of TEC family
kinases have been used to treat
COVID-19. Overall, this study provides important information toward identifying potential
biomarkers and therapeutic targets for
COVID-19 disease.